Bernhard Ultsch
Title
Cited by
Cited by
Year
Epidemic profile of Shiga-toxin–producing Escherichia coli O104: H4 outbreak in Germany
C Frank, D Werber, JP Cramer, M Askar, M Faber, M an der Heiden, ...
New England Journal of Medicine 365 (19), 1771-1780, 2011
12802011
Large and ongoing outbreak of haemolytic uraemic syndrome, Germany, May 2011
C Frank, MS Faber, M Askar, H Bernard, A Fruth, A Gilsdorf, M Höhle, ...
Eurosurveillance 16 (21), 19878, 2011
2092011
Herpes zoster in Germany: quantifying the burden of disease
B Ultsch, A Siedler, T Rieck, T Reinhold, G Krause, O Wichmann
BMC infectious diseases 11 (1), 1-8, 2011
1122011
Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany
B Ultsch, I Köster, T Reinhold, A Siedler, G Krause, A Icks, I Schubert, ...
The European Journal of Health Economics 14 (6), 1015-1026, 2013
822013
Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community
B Ultsch, O Damm, P Beutels, J Bilcke, B Brüggenjürgen, A Gerber-Grote, ...
Pharmacoeconomics 34 (3), 227-244, 2016
792016
Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany
B Ultsch, F Weidemann, T Reinhold, A Siedler, G Krause, O Wichmann
BMC health services research 13 (1), 1-18, 2013
512013
Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries
O Damm, B Ultsch, J Horn, RT Mikolajczyk, W Greiner, O Wichmann
BMC Public Health 15 (1), 1-19, 2015
422015
A systematic review of the health economic consequences of quadrivalent influenza vaccination
PT de Boer, BM van Maanen, O Damm, B Ultsch, FCK Dolk, P Crépey, ...
Expert review of pharmacoeconomics & outcomes research 17 (3), 249-265, 2017
392017
Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero® to reduce meningococcal group B disease in Germany
H Christensen, T Irving, J Koch, CL Trotter, B Ultsch, F Weidemann, ...
Vaccine 34 (29), 3412-3419, 2016
362016
Cost-effectiveness of human papillomavirus vaccination in Germany
O Damm, J Horn, RT Mikolajczyk, MEE Kretzschmar, AM Kaufmann, ...
Cost Effectiveness and Resource Allocation 15 (1), 1-19, 2017
282017
Current and future effects of varicella and herpes zoster vaccination in Germany–Insights from a mathematical model in a country with universal varicella vaccination
J Horn, A Karch, O Damm, ME Kretzschmar, A Siedler, B Ultsch, ...
Human vaccines & immunotherapeutics 12 (7), 1766-1776, 2016
272016
Cost-effectiveness of childhood rotavirus vaccination in Germany
P Aidelsburger, K Grabein, K Böhm, M Dietl, J Wasem, J Koch, B Ultsch, ...
Vaccine, 2014
272014
Is the impact of childhood influenza vaccination less than expected: a transmission modelling study
F Weidemann, C Remschmidt, S Buda, U Buchholz, B Ultsch, ...
BMC infectious diseases 17 (1), 1-14, 2017
242017
Influence of demographic changes on the impact of vaccination against varicella and herpes zoster in Germany - a mathematical modelling study
Horn J, Damm O, Greiner W, Hengel H, Kretzschmar ME, Siedler A, Ultsch B ...
BMC Med 16 (1), 3, 2018
16*2018
Effectiveness, population-level effects, and heath economics of measles and rubella vaccination
O Wichmann, B Ultsch
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 56 (9), 1260 …, 2013
15*2013
Epidemiology and cost of seasonal influenza in Germany-a claims data analysis
S Scholz, O Damm, U Schneider, B Ultsch, O Wichmann, W Greiner
BMC Public Health 19 (1), 1-10, 2019
132019
Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany
A Siedler, J Koch, B Ultsch, E Garbe, R von Kries, T Ledig, T Mertens, ...
Bundesgesundheitsbl 60 (60), 1162-79, 2017
102017
The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany
S Scholz, F Koerber, K Meszaros, RM Fassbender, B Ultsch, RR Welte, ...
Vaccine 37 (12), 1692-1701, 2019
92019
Standardisierte Kostenberechnungen im deutschen Gesundheitswesen: Bericht der Arbeitsgruppe „Standardkosten “des Ausschusses „ökonomische Evaluation “der dggö
S Scholz, J Biermann-Stallwitz, C Brettschneider, O Damm, A Freytag, ...
Gesundheitsökonomie & Qualitätsmanagement 25 (01), 52-59, 2020
42020
Health Economics In immunization decision-making–results from a systematic literature research and a stakeholder symposium In Germany
B Ultsch, O Damm, M Perleth, O Wichmann
Value in Health 18 (7), A569, 2015
42015
The system can't perform the operation now. Try again later.
Articles 1–20